Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

Diabetes

Volumn 47, Issue 11, 1998, Pages 1663-1670

  Holst, Jens J ^a,b   Deacon, Carolyn F ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1;

CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME DEGRADATION; ENZYME INHIBITION; GASTROINTESTINAL TRACT EXAMINATION; HORMONE RELEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SATIETY; SIDE EFFECT;

ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PEPTIDE FRAGMENTS; PEPTIDES; PROTEASE INHIBITORS; PROTEIN PRECURSORS;

EID: 0031690479     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.11.1663     Document Type: Review

References (81)

1. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase TV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, and peptíde histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
2. Buckley DI, Lundquist P: Analysis of the degradation of insulinotropin (GLP-1 7-37) in human plasma and production of degradation resistant analogs (Abstract). Regul Pept 40:117A, 1992
3. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
4. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann B, Layer P, Reeve JR, Eysselein VE, Goebell H, Müller M: Is GLP-1 (9-36)amide an endogenous antagonist at GLP-1 receptors? (Abstract). Digestion 55:302A, 1994
5. Knudsen LB, Pridal L: Glucagon-like peptide-1 (9-36)amide is a major metabolite of glucagon-like peptide-1 (7-36)amide after in vivo administration to dogs, and acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435, 1996.
6. Wettergren A, Wøjdemann M, Holst JJ: Glucagon-like peptide-1 (7-36)amide's inhibitory effect on antral motility is antagonised by its N-terminally truncated gon-like peptide 1 (9-36)amide. Peptides 19:877-882, 1998
7. Deacon CF, Nauck MA, Toft-Nielsen M-B, Pridal L, Willms B, Holst JJ: Both subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type 2 diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
8. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with type 2-diabetes. Diabetologia 39:1546-1553, 1996
9. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-464, 1996
10. Ørskov C, Wettergren A, Holst JJ: The metabolic rate and the biological effects of GLP-1 7-36amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes 42:658-661, 1993
11. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41:271-278, 1998
12. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig. Diabetes 47:764-769, 1998
13. Pauly RP, Demuth HU, Rosche P, Schmidt J, White HA, McIntosh CHS, Pederson RA: Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance (Abstract). Regul Pept 64:A148, 1996
14. Balkan B, Kwasnik L, Miserendino R, Mone M, Hughes TE, Li X: Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese Zucker rats (Abstract). Diabetologia 40 (Suppl. 1):A131, 1997
15. Li X, Kwasnik L, Miserendino R, Mone M, Hughes TE, Villhauer EB, Balkan B: Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in insulin resistant rats (Abstract). Diabetes 46 (Suppl. 1):273A, 1997
16. Fleischer B: CD26: a surface protease involved in T-cell activation. Immunol Today 15:180-184, 1994
17. Toromoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C: Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 147:2514-2517, 1991
18. Hegen M, Mittrucker HW, Hug R, Demuth HU, Neubert K, Barth A, Fleischer B: Enzymatic activity of CD26 (dipeptidyl peptidase IV) is not required for its signalling function in T cells. Immunobiology 189:483-493, 1993
19. Steeg C, Hartwig U, Fleischer B: Unchanged signalling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. Cell Immunol 164:311-315, 1995
20. Kahne T, Neubert K, Ansorge S: Enzymatic activity of DPIV/CD26 is involved in PMA-induced hyperphosphorylation of p561ck. Immunol Lett 46:189-193, 1995
21. Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossmann SF, Morimoto C: Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 91:3082-3086, 1994
22. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C: The costimula- tory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 90:4586-4590, 1993
23. Von Bonin A, Hühn J, Fleischer B: Dipeptidyl-peptidase IV/CD 26 on T-cells: analysis of an alternative T-cell activation pathway. Immunol Rev 161:43-53, 1998
24. Schön E, Born I, Demuth H-U, Faust J, Neubert K, Steinmetzer T, Barth A, Ansorge S: Dipeptidyl peptidase IV in the immune system: effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe-Seyler 372:305-311, 1991
25. Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CHS: The enteroinsular axis in dipeptidyl peptidase IV- negative rats. Metabolism 45:1335-1341, 1996.
26. Iwaki-Egawa S, Watanabe Y, Fujimoto Y: Is CD26/dipeptidyl peptidase IV a really important molecule in T cell activation of a certain rat strain? Immunobiology 194:429-442, 1995
27. De Meester I, Belyaev A, Lambeir AM, De Meyer GR, Van Osselaer N, Haemers A, Scharpe S: In vivo inhibition of dipeptidyl peptidase IV activity by pro-prodiphenyl-phosphonate (Prodipine). Biochem Pharmacol 54:173-179, 1997
28. Holst JJ, Hansen L, Ørskov C, Wøjdemann M, Wettergren A, Deacon CF: GLP-1 (7-36amide) is transformed by dipeptidyl peptidase IV in the capillaries supplying the L-cells into GLP-1 (9-36amide), which antagonizes the gastrointestinal effects of GLP-1 (Abstract). Diabetes 47 (Suppl. 1):A30, 1998
29. Mentlein R, Dahms P, Grandt D, Kruger R: Proteolytic processing of neuropeptide Y and peptide YY by dipetidylpeptidase IV. Regul Pept 49:133-144, 1993
30. Grandt D, Schimiczek M, Beglinger Ch, Layer P, Goebell H, Eysselein VE, Reeve JR: Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151-159, 1994
31. Grandt D, Teyssen S, Schimiczek M, Reeve JR Jr, Feth F, Rascher W, Hirche H, Singer MV, Layer P, Goebell H: Novel generation of hormone receptor specificity by amino terminal processing of peptide Y. Biochem Biophys Res Commun 186:1299-1306, 1992
32. Wettergren A, Maina P, Boesby S, Holst JJ: Glucagon-like peptide-1 7-36amide and peptide YY have additive inhibitory effects on gastric acid secretion in man. Scand J Gastroenterol 32:552-555, 1997
33. Holst JJ: Enteroglucagon. Ann Rev Physiol 59:257-272, 1997
34. Sheikh S: Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function. Am J Physiol 261:G701-G715, 1991
35. Whang EE, Hines OJ, Reeve JR Jr, Grandt D, Moser JA, Bilchik AJ, Zinner MJ, McFadden DW, Ashley SW: Antisecretory mechanism of peptide YY in rat distal colon. Dig Dis Sci 42:1121-1127, 1997
36. Lloyd KC, Grandt D, Aurang K, Eysselein VE, Schimiczek M, Reeve JR Jr: Inhibitory- effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y1 receptors. Am J Physiol 270:G123-G127, 1996
37. Frohman LA, Downs TR, Heimer EP, Felix AM: Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 85:1533-1540, 1989
38. Kubiak TM, Martin RA, Leone JW, Cleary DL: Metabolism of mouse growth hormone-releasing factor, mGRF (1-42)OH, and selected analogs from the boxine GRF series in mouse and bovine plasma in vitro. Pept Res 7:153-161, 1994
39. Larsen J, Jallad N, Damsbo P: One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM 28Abstract). Diabetes 45 (Suppl. 2):233A, 1996
40. Larsen J, Damsbo P: GLP-1 must be present continuously in order to obtain a good glycemic control in NIDDM (Abstract). Diabetes 46 (Suppl. 1):186A, 1997
41. Burcelin R, Roland E, Dolci W, Carrel V, Thorens B: A novel gene therapy approach for the treatment of NIDDM based on encapsulated cells secreting GLP-1 (Abstract). Diabetes 47 (Suppl. 1):A67, 1998
42. Nauck MA, Kemmeries G, Grosser S, Ørskov C, Holst JJ. Schmiegel S: Rapid tachyphylaxis for the deceleration of gastric emptying by exogenous GLP-1 (Abstract). Gastroenterology 112 (Suppl.):A797, 1997
43. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemic by exogenous GLP-1 (7-36amide) in type 2-diabetic patients. Diabetologia 36:741-744, 1993
44. Ørskov C, Wettergren A, Holst JJ: Secretion of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665-670, 1996
45. Toft-Nielsen M-B, Madsbad S, Holst JJ: The effect of GLP-1 on glucose elimination. Diabetes 45:552-556, 1996
46. Vaag A, Holst JJ, Vølund A, Beck-Nielsen H: Gut incretin hormones in identical twins discordant for NIDDM: evidence for decreased GLP-1 secretion during oral glucose in NIDDM twins. Eur J Endocrinol 135:425-432, 1996
47. Nauck M, Stöckmann R, Ebert R, Creutzfeldt W: Reduced incretin effect in type-2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52, 1986
48. Holst JJ, Gromada J, Nauck MA: The pathogenesis of non-insulin dependent diabetes mellitus involves a defective expression of the GIP receptor. Diabetologia 40:984-986, 1997
49. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of GLP-1 (7-36amide) but not of synthetic human GIP in patients with type 2 diabetes mellitus. J Clin Invest 36:741-744, 1993
50. Toft-Nielsen M-B, Madsbad S, Holst JJ: Continuous subcutaneous infusion of glucagon-like peptide-1 (GLP-1) lowers blood glucose and reduces appetite in NIDDM patients (Abstract). Diabetes 47 (Suppl. 1):A100, 1998
51. Nauck MA, Holst JJ, Willms B: Glucagon-like peptide-1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29:411-116, 1997
52. Toft-Nielsen M-B, Madsbad S, Holst JJ: IV GLP-1 lowers blood glucose levels in NIDDM patients regardless of fasting glucose, BMI and insulin capacity (Abstract). Diabetologia 40 (Suppl. 1):A129, 1997
53. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 [7-36 amide] in type 1 diabetic patients. Diabetes Care 19:580-586, 1996
54. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh D, Elahi D, Egan JM: Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99:2883-2889, 1997
55. De Ore K, Greig NH, Holloway HW, Wang Y, Perfetti R, Egan JM: The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test. J Gerontol A Biol Sci Med Sci 52:B245-B249, 1997
56. Zhou J, Wang X, Egan JM: Glucagon-like peptide-1 converts amylase secreting AR42J cells into insulin-secreting cells (Abstract). Diabetes 47 (Suppl. 1):A72, 1998
57. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W: Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36amide] in the fasting state in healthy subjects. Acta Diabetologica 32:13-16, 1995
58. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA:Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
59. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide- 1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
60. Kreymann B, Ghatei MA. Williams G, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 11:1300-1304, 1987
61. Miholic J, Ørskov C, Holst JJ, Kotzer JJ, Meyer HJ: Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1). and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36:1361-1370, 1991
62. Toft-Nielsen M-B, Madsbad S, Holst JJ: Exaggerated secretion of glucagon-like peptide-1 (GLP-1) can explain postprandial reactive hypoglycemia in patients with accelerated gastric emptying. Diabetologia. In press
63. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520, 1998
64. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM: Energy intake and appetite is suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Intern J Obes. In press
65. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36amide] after subcutaneous injection in healthy volunteers: dose-response-relationship. Diabetologia 38:720-725, 1995
66. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL: Induction of intestinal epithelial proliferation by glucagon-like peptide-2. Proc Natl Acad Sci U S A 93:7911-7916, 1996
67. Drucker DJ, Shi Q, Crivici A, Sumner-Smitt M. Tavares W, Hill M, Deforest L, Cooper S, Brubaker PL: Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nature Biotech 15:673-677, 1997
68. Hartmann B, Deacon CF, Ørskov C, Johnsen AH, Holst JJ: Structure, analysis, secretion and metabolism of human glucagon-like peptide-2 (Abstract). Regul Pept. In press
69. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH: Endocrine tumor in kidney affecting small bowel structure, motility, and absorptive function. Gut 12:77:3-782, 1971
70. Larsen PJ, Tang-Christensen M, Holst JJ, Ørskov C: Distribution of glucagon-like peptide-1 (GLP-1) and other preproglucagon derived peptides in the rat hypothalamus and brain stem. Neuroscience 77:257-270, 1997
71. Larsen PJ, Tang-Christensen M, Jessop DS: Central administration of glucagon-like peptide-1 activates neuroendocrine neurons in the rat. Endocrinology 138:444:5-4455, 1997
72. Turton MD, O' Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the regulation of feeding. Nature 379:69-72, 1996
73. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP: Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856, 1996
74. Mitro A, Lojda Z: Histochemistry of proteases in ependyma, choroid plexus and leptomeninges. Histochemistry 88:645-646, 1988
75. Nagy JI, Yamamoto T, Uemura H, Schrader WP: Adenosine deaminase in rodent median eminence: detection by antibody to the mouse enzyme and co-localisation with adenosine deaminase-complexing protein (CD26). Neuroscience 73:459-471, 1996
76. Mentzel S, Dijkman HBPM, Van Son JPHF, Koene RAP, Assmann KJM: Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 44:445-461, 1996
77. Mitro A, De Bault LE: Enzyme histochemical studies of membrane proteases in rat subfornical organ. Acta Histochem 96:366-364, 1994
78. Hartel-Schenk S, Gossrau R, Reutter W: Comparative immunohistochemistry and histochemistry of dipeptidyl peptidase IV in rat organs during development. Histochem J 22:567-578, 1990
79. Wada K, Yokotani N, Hunter C, Doi K, Wenthold RJ, Shimasaki S: Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci USA 89:197-201, 1992
80. de Lecea L, Soriano E, Criado JR, Steffensen SC, Henriksen SJ, Sutcliffe JG: Transcripts encoding a neural membrane CD26 peptidase-like protein are stimulated by synaptic activity. Brain Res Mol Brain Res 25:286-296, 1994
81. Grandt D, Schimiczek M, Rascher W, Feth F, Shively JJ, Lee TD, Davis MT, Reeve JR Jr, Michel MC: Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul Pept 67:33-37, 1996